ISSN: 2161-0681

Revista de patología clínica y experimental

Acceso abierto

Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Indexado en
  • Índice Copérnico
  • Google Académico
  • sherpa romeo
  • Abrir puerta J
  • Revista GenámicaBuscar
  • TOC de revistas
  • Directorio de publicaciones periódicas de Ulrich
  • Búsqueda de referencia
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • publones
  • Fundación de Ginebra para la educación y la investigación médicas
  • Pub Europeo
  • ICMJE
Comparte esta página

Abstracto

Comparison of Original and Internal Pathology Reports Referred for UrothelialCarcinoma to Determine Rate of Discrepancies and the Impact on Treatment Decisions

Luisa Cioci, La Mont Barlow, Edan Shapiro, Jennifer Ahn, Mitchell Benson, Guarionex J De Castro and James Mc Kiernan

Objective: The purpose of the current study is to perform a standardized comparison of original and internal repeat pathology reviews of identical bladder specimens to identify discrepancies and characterize the impact of repeat review on treatment decisions as well as identify patients most likely to benefit from this practice.

Materials/Methods: Ninety-one patients with an outside diagnosis of urothelial cancer of the bladder were referred to our institution for repeat review of 91 bladder resection specimens and biopsies.

A discrepancy in either the presence or absence of muscularis propria and presence of invasive disease in the muscularis propria was deemed a “treatment-altering” characteristic, while presence of carcinoma in situ, lymphovascular invasion, or micropapillary features was deemed a “clinically-significant” characteristic.

Results: After repeat review at our institution, 29.7% (27) specimens had treatment altering discrepancies, and 61.5% (56) specimens had at least one clinically-significant discrepancy.

Conclusion: Repeat review of referred bladder specimens frequently impacts treatment decisions in patients with urothelial carcinoma.